EMT Cancer Research Results

EMT, Epithelial-Mesenchymal Transition: Click to Expand ⟱
Source:
Type:
Biological process in which epithelial cells lose their cell polarity and cell-cell adhesion properties and gain mesenchymal traits, such as increased motility and invasiveness. This process is pivotal during embryogenesis and wound healing. Hh signaling pathway is able to regulate the EMT. Snail, E-cadherin and N-cadherin, key components of EMT; EMT-related factors, E-cadherin, N-cadherin, vimentin; The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin.
EMT is regulated by various signaling pathways, including TGF-β, Wnt, Notch, and Hedgehog pathways. Transcription factors such as Snail, Slug, Twist, and ZEB play critical roles in repressing epithelial markers (like E-cadherin) and promoting mesenchymal markers (like N-cadherin and vimentin).
EMT is associated with increased tumor aggressiveness, enhanced migratory and invasive capabilities, and resistance to apoptosis.
Scientific Papers found: Click to Expand⟱
2881- HNK,    Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis
- in-vitro, PC, PANC1
tumCV↓, Casp3↑, Apoptosis↑, TumCCA↑, TumCI↓, Mcl-1↓, EMT↓,
2882- HNK,    Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling
- in-vitro, PC, PANC1
TumCI↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, Snail↓, Slug↓, Rho↓, ROCK1↓,
2883- HNK,    Honokiol targets mitochondria to halt cancer progression and metastasis
- Review, Var, NA
ChemoSen↑, BBB↓, Ca+2↑, Cyt‑c↑, Casp3↑, chemoPv↑, OCR↓, mitResp↓, Apoptosis↑, RadioS↑, NF-kB↓, Akt↓, TNF-α↓, PGE2↓, VEGF↓, NO↝, COX2↓, RAS↓, EMT↓, Snail↓, N-cadherin↓, β-catenin/ZEB1↓, E-cadherin↑, ER Stress↑, p‑STAT3↓, EGFR↓, mTOR↓, mt-ROS↑, PI3K↓, Wnt↓,
2884- HNK,    Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP
- in-vitro, Lung, A549 - in-vitro, Lung, H460
EMT↓, cFLIP↓, N-cadherin↓, Snail↓, p‑SMAD2↓, p‑SMAD3↓, IKKα↑, TumCMig↓,
2866- HNK,    Honokiol and its analogues as anticancer compounds: Current mechanistic insights and structure-activity relationship
- Review, Var, NA
EMT↓, TumMeta↓, BioAv↑, BBB↑,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
2891- HNK,    Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs
- Review, Var, NA
AntiCan↑, Inflam↓, antiOx↑, selectivity↑, *toxicity↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, TumMeta↓, NADPH↓, MMP2↓, MMP9↓, p‑mTOR↓, EGFR↓, EMT↓, SIRT1↑, SIRT3↑, EZH2↓, Snail↓, Vim↓, N-cadherin↓, E-cadherin↑, COX2↓, NF-kB↓, *ROS↓, Ca+2↑, ROS↑,
4636- HT,    Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/ß-catenin and TGFß signaling
- in-vitro, BC, SUM159 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, HS587T - in-vitro, BC, BT549
Wnt↓, β-catenin/ZEB1↓, LRP6↓, cycD1/CCND1↓, EMT↓, Slug↓, Zeb1↓, Snail↓, Vim↓, TGF-β↓, CSCs↓, TumCMig↓, chemoP↑,
4640- HT,    The anti-cancer potential of hydroxytyrosol
- Review, Var, NA
selectivity↑, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, Bcl-2↓, BAX↑, MPT↑, Fas↑, PI3K↓, Akt↓, mTOR↓, Mcl-1↓, survivin↓, STAT3↓, EMT↓, TumCI↓, angioG↓, E-cadherin↑, N-cadherin↓, Snail↓, Twist↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, VEGFR2↓, Hif1a↓, CSCs↓, CD44↓, Wnt↓, β-catenin/ZEB1↓,
4632- HT,    Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vitro, BC, SUM159
CSCs↓, TumCMig↓, TumCI↓, β-catenin/ZEB1↓, Wnt↓, p‑LRP6↓, LRP6↓, cycD1/CCND1↓, EMT↓, Slug↓, Zeb1↓, Snail↓, Vim↓, SMAD2↓, SMAD3↓, TGF-β↓,
1168- IVM,  SRF,    Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
- in-vitro, HCC, NA
TumMeta↓, mTOR↓, EMT↓, CSCsMark↓, STAT3↓,
5115- JG,    Natural Products to Fight Cancer: A Focus on Juglans regia
- Review, Var, NA
Casp3↑, Casp9↑, MMP↓, AR↓, PSA↓, E-cadherin↑, N-cadherin↓, Vim↓, Akt↓, GSK‐3β↓, EMT↑, TumCI↓, MMP9↓, VEGF↓, MMP2↓, TumCCA↑, ROS↑, Apoptosis↑, GSH↓, Catalase↓, SOD↓, GPx↓, DNAdam↑, γH2AX↑, eff↑, BAX↑, Fas↑, Pin1↓,
1266- LE,    Glycyrrhizin suppresses epithelial-mesenchymal transition by inhibiting high-mobility group box1 via the TGF-β1/Smad2/3 pathway in lung epithelial cells
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B
HMGB1↓, EMT↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓,
1122- LF,  MTX,    Lactoferrin Reverses Methotrexate Driven Epithelial Barrier Defect by Inhibiting TGF-β Mediated Epithelial to Mesenchymal Transition
- in-vivo, Colon, Caco-2
TGF-β↓, EMT↓,
1100- LT,    Luteolin, a flavonoid, as an anticancer agent: A review
- Review, NA, NA
TumCP↓, TumCCA↑, Apoptosis↑, EMT↓, E-cadherin↑, N-cadherin↓, Snail↓, Vim↓, ROS↑, ER Stress↑, mtDam↑, p‑eIF2α↝, p‑PERK↝, p‑CHOP↝, p‑ATF4↝, cl‑Casp12↝,
4687- LT,  QC,    Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells
- in-vitro, Pca, DU145
CSCs↓, EMT↓, MMPs↓, TumCMig↓, TumCI↓,
2912- LT,    Luteolin: a flavonoid with a multifaceted anticancer potential
- Review, Var, NA
ROS↑, TumCCA↑, TumCP↓, angioG↓, ER Stress↑, mtDam↑, PERK↑, ATF4↑, eIF2α↑, cl‑Casp12↑, EMT↓, E-cadherin↑, N-cadherin↓, Vim↓, *neuroP↑, NF-kB↓, PI3K↓, Akt↑, XIAP↓, MMP↓, Ca+2↑, BAX↑, Casp3↑, Casp9↑, Bcl-2↓, Cyt‑c↑, IronCh↑, SOD↓, *ROS↓, *LDHA↑, *SOD↑, *GSH↑, *BioAv↓, Telomerase↓, cMyc↓, hTERT/TERT↓, DR5↑, Fas↑, FADD↑, BAD↑, BOK↑, BID↑, NAIP↓, Mcl-1↓, CDK2↓, CDK4↓, MAPK↓, AKT1↓, Akt2↓, *Beclin-1↓, Hif1a↓, LC3II↑, Beclin-1↑,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2916- LT,    Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies
- Review, Var, NA - Review, AD, NA - Review, Park, NA
proCasp9↓, CDC2↓, CycB/CCNB1↓, Casp9↑, Casp3↑, Cyt‑c↑, cycA1/CCNA1↑, CDK2↓, APAF1↑, TumCCA↑, P53↑, BAX↑, VEGF↓, Bcl-2↓, Apoptosis↑, p‑Akt↓, p‑EGFR↓, p‑ERK↓, p‑STAT3↓, cardioP↑, Catalase↓, SOD↓, *BioAv↓, *antiOx↑, *ROS↓, *NO↓, *GSTs↑, *GSR↑, *SOD↑, *Catalase↑, *lipid-P↓, PI3K↓, Akt↓, CDK2↓, BNIP3↑, hTERT/TERT↓, DR5↑, Beclin-1↑, TNF-α↓, NF-kB↓, IL1↓, IL6↓, EMT↓, FAK↓, E-cadherin↑, MDM2↓, NOTCH↓, MAPK↑, Vim↓, N-cadherin↓, Snail↓, MMP2↓, Twist↓, MMP9↓, ROS↑, MMP↓, *AChE↓, *MMP↑, *Aβ↓, *neuroP↑, Trx1↑, ROS↓, *NRF2↑, NRF2↓, *BBB↑, ChemoSen↑, GutMicro↑,
1126- Lyco,    Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway
- vitro+vivo, Oral, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, PI3K↓, Akt↓, mTOR↓, E-cadherin↓, BAX↑, N-cadherin↓, p‑PI3K↓, p‑Akt↓, p‑mTOR↓, Bcl-2↓,
1714- Lyco,    Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load
- in-vitro, Ovarian, OV-MZ-6 - in-vivo, NA, NA
ChemoSen↑, CA125↓, ITGA5↓, ITGB1↓, MMP9↓, FAK↓, EMT↓, MAPK↓, MMP9↓, antiOx↑, Ki-67↓, MAPK↓,
4795- Lyco,    Updates on the Anticancer Profile of Lycopene and its Probable Mechanism against Breast and Gynecological Cancer
- Review, BC, NA
TumCG↓, TumCCA↑, Apoptosis↑, P53↝, BAX↝, cycD1/CCND1↓, ERK↓, Akt↓, STAT3↓, NRF2↝, NF-kB↓, ITGB1↓, ITGA5↓, FAK↓, MMP9↓, EMT↓,
4520- MAG,    Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling
- vitro+vivo, PC, PANC1
Vim↓, E-cadherin↑, EMT↓, N-cadherin↓, p‑SMAD2↓, p‑SMAD3↓, TumCP↓, TumCMig↓, TumCI↓, TGF-β↓,
2376- MET,    Metformin Inhibits Epithelial-to-Mesenchymal Transition of Keloid Fibroblasts via the HIF-1α/PKM2 Signaling Pathway
- in-vitro, Nor, NA
*Hif1a↓, *EMT↓, *p‑P70S6K↓, *PKM2↓,
2371- MET,    The role of pyruvate kinase M2 in anticancer therapeutic treatments
- Review, Var, NA
ChemoSen↑, PKM2↓, Hif1a↓, EMT↓,
2377- MET,    Metformin Inhibits TGF-β1-Induced Epithelial-to-Mesenchymal Transition via PKM2 Relative-mTOR/p70s6k Signaling Pathway in Cervical Carcinoma Cells
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa
EMT↓, P70S6K↓, mTOR↓, PKM2↓, Warburg↓, AMPK↑,
2378- MET,    Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway
- in-vitro, SCC, CAL27 - in-vivo, NA, NA
TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,
2384- MET,    Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication
- in-vitro, Thyroid, BCPAP - in-vivo, NA, NA - in-vitro, Thyroid, TPC-1
Glycolysis↓, OXPHOS↑, tumCV↓, TumCI↓, TumCMig↓, EMT↓, Apoptosis↑, TumCCA↑, LDHA↓, PKM2↓, IDH1↑, TumCG↓,
2386- MET,    Mechanisms of metformin inhibiting cancer invasion and migration
- Review, Var, NA
OS↑, AMPK↑, EMT↓, TGF-β↓, mTOR↓, P70S6K↓, PKM2↓, Hif1a↓, ChemoSen↑,
1141- Myr,    Myricetin: targeting signaling networks in cancer and its implication in chemotherapy
- Review, NA, NA
*PI3K↑, *Akt↑, p‑Akt↓, SIRT3↑, p‑ERK↓, p38↓, VEGF↓, MEK↓, MKK4↓, MMP9↓, Raf↓, F-actin↓, MMP2↓, COX2↓, BMP2↓, cycD1/CCND1↓, Bax:Bcl2↑, EMT↓, EGFR↓, TumAuto↑,
1799- NarG,    Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics
- Review, NA, NA
TumCCA↑, BioAv↑, Half-Life∅, TNF-α↓, Casp8↑, BAX↑, Bak↑, EGF↓, mTOR↓, PI3K↓, ERK↓, Akt↓, NF-kB↓, VEGF↓, angioG↓, antiOx↑, EMT↓, OS↑, MAPK↓, ChemoSen↑, MMP9↓, MMP2↓, ROS↑, ROS↑, GSH↓, Casp3↑, ROS↑,
1129- NarG,    Naringenin Attenuated Prostate Cancer Invasion via Reversal of Epithelial-to-Mesenchymal Transition and Inhibited uPA Activity
- in-vitro, Pca, PC3
E-cadherin↓, Vim↓, Snail↓, Twist↓, EMT↓, uPA↓,
5253- NCL,    Niclosamide: Beyond an antihelminthic drug
- Review, Var, NA
TumCP↓, Apoptosis↑, EMT↓, β-catenin/ZEB1↓, TumCG↓, toxicity↓, Wnt↓, LRP6↓, eff↑, DR5↑, mTORC1↓, pH↓, CSCs↓, IL6↓, JAK1↓, STAT3↓, ChemoSen↑, TumCG↓, tumCV↓, NOTCH↓, NF-kB↓, EGFR↓, ROS↑, RadioS↑, cFos↓, cJun↓, E2Fs↓, cMyc↓, Half-Life↓, BioAv↝,
4976- Nimb,    Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition
- vitro+vivo, PC, NA
ROS↑, Apoptosis↑, TumAuto↑, TumCP↓, TumCMig↓, TumCI↓, EMT↓, Dose↓, selectivity↑, Akt↓, eff↓, BAX↑, cl‑Casp3↑, cl‑PARP↑, Bcl-2↓,
4977- Nimb,    Nimbolide Inhibits SOD2 to Control Pancreatic Ductal Adenocarcinoma Growth and Metastasis
- vitro+vivo, PC, AsPC-1 - in-vitro, PC, PANC1
SOD2↑, TumCG↓, TumMeta↓, ROS↑, Apoptosis↑, PI3K↓, Akt↓, EMT↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑PARP↑, Bcl-2↓,
4646- OLEC,    Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology
- Review, Var, NA
BioAv↓, *Inflam↓, *antiOx↓, cMET↓, STAT3↓, TNF-α↓, COX2↓, EMT↓, angioG↓, *GutMicro↝, eff↑,
1673- PBG,    An Insight into Anticancer Effect of Propolis and Its Constituents: A Review of Molecular Mechanisms
- Review, Var, NA
TumCP↓, Apoptosis↑, TumCCA↑, MALAT1↓, P53↑, RadioS↑, OS↑, ROS↑, NF-kB↓, p65↑, MMP↓, ROS↑, MMP9↓, β-catenin/ZEB1↓, Vim↓, E-cadherin↓, VEGF↓, EMT↓,
3257- PBG,    The Potential Use of Propolis as a Primary or an Adjunctive Therapy in Respiratory Tract-Related Diseases and Disorders: A Systematic Scoping Review
- Review, Var, NA
CDK4↓, CDK6↓, pRB↓, ROS↓, TumCCA↑, P21↑, PI3K↓, Akt↓, EMT↓, E-cadherin↑, Vim↓, *COX2↓, *MPO↓, *MDA↓, *TNF-α↓, *IL6↓, *Catalase↑, *SOD↑, *AST↓, *ALAT↓, *IL1β↓, *IL10↓, *GPx↓, *TLR4↓, *Sepsis↓, *IFN-γ↑, *GSH↑, *NRF2↑, *α-SMA↓, *TGF-β↓, *IL5↓, *IL6↓, *IL8↓, *PGE2↓, *NF-kB↓, *MMP9↓,
4922- PEITC,    Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms
- Review, Var, NA
Risk↓, AntiCan↑, TumCP↓, TumMeta↓, ChemoSen↑, *BioAv↑, *other↝, *Dose↝, Dose↓, *BioAv↑, *Dose↝, *Half-Life↝, *toxicity↝, GSH↓, ROS↑, CYP1A1↑, CYP1A2↑, P450↓, CYP2E1↑, CYP3A4↓, CYP2A3/CYP2A6↓, *ROS↓, *GPx1↑, *SOD1↑, *SOD2↑, Akt↓, EGFR↓, HER2/EBBR2↓, P53↑, Telomerase↓, selectivity↑, MMP↓, Cyt‑c↑, Apoptosis↑, DR4↑, Fas↑, XIAP↓, survivin↓, TumAuto↑, Hif1a↓, angioG↓, MMPs↓, ERK↓, NF-kB↓, EMT↓, TumCI↓, TumCMig↓, Glycolysis↓, ATP↓, selectivity↑, *antiOx↑, Dose↝, other↝, OCR↓, GSH↓, ITGB1↓, ITGB6↓, ChemoSen↑,
4926- PEITC,    PEITC inhibits the invasion and migration of colorectal cancer cells by blocking TGF-β-induced EMT
- in-vitro, CRC, SW48
TumCI↓, TumCMig↓, EMT↓, Smad1↓, AntiCan↑, Snail↓, Slug↓, Zeb1↓, ZEB2↓, TGF-β1↓, eff↑, E-cadherin↑, N-cadherin↓, Vim↓,
1258- PI,    Piperlongumine Alleviates Mouse Colitis and Colitis-Associated Colorectal Cancer
- in-vivo, CRC, NA
COX2↓, IL6↓, EMT↓, β-catenin/ZEB1↓, Snail↓, Symptoms∅,
1257- PI,    Piperlongumine attenuates bile duct ligation-induced liver fibrosis in mice via inhibition of TGF-β1/Smad and EMT pathways
- ex-vivo, LiverDam, NA
*Fibronectin↓, *α-SMA↓, *COL1↓, *COL3A1↓, *TGF-β↓, *EMT↓, *MMP2↓, *α-SMA↓, *Smad7↑, *E-cadherin↑, *Vim↓, *hepatoP↑, *antiOx↑, *GSH↑, *ROS↓,
1256- PI,    Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models
- in-vitro, adrenal, PHEO - in-vivo, NA, NA
Apoptosis↑, ROS↑, TumCMig↓, TumCI↓, EMT↓, angioG↓, Necroptosis↑, MAPK↑, ERK↑,
5211- PI,    Piperine inhibits colorectal cancer migration and invasion by regulating STAT3/Snail-mediated epithelial-mesenchymal transition
- in-vitro, CRC, NA
TumCMig↓, TumCI↓, EMT↓, Snail↓, STAT3↓,
1131- PI,    Piperlongumine‑loaded nanoparticles inhibit the growth, migration and invasion and epithelial‑to‑mesenchymal transition of triple‑negative breast cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549
TumCG↓, tumCV↓, TumCMig↓, TumCI↓, MMP2↓, Slug↓, N-cadherin↓, β-catenin/ZEB1↓, SMAD3↓, E-cadherin↑, EMT↓,
1059- PI,    Piperine Inhibits TGF-β Signaling Pathways and Disrupts EMT-Related Events in Human Lung Adenocarcinoma Cells
- in-vitro, Lung, A549 - in-vitro, BC, MDA-MB-231 - in-vitro, Liver, HepG2
EMT↓, p‑ERK↓, p‑SMAD2↓,
2973- PL,    The Natural Alkaloid Piperlongumine Inhibits Metastatic Activity and Epithelial-to-Mesenchymal Transition of Triple-Negative Mammary Carcinoma Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1
MMP2↓, MMP9↓, IL6↓, E-cadherin↑, ROS↑, EMT↓, Zeb1↓, Slug↓, TumMeta↓, selectivity↑, MMP2↓, GSH↓,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
2952- PL,    Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization
- in-vitro, Bladder, T24/HTB-9 - in-vivo, Bladder, NA
TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, ROS↑, Slug↓, β-catenin/ZEB1↓, Zeb1↓, N-cadherin↓, F-actin↓, GSH↓, EMT↓, CLDN1↓, ZO-1↓,

Showing Research Papers: 151 to 200 of 285
Prev Page 4 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 285

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   Catalase↓, 3,   CYP1A1↓, 1,   CYP1A1↑, 1,   CYP2E1↑, 1,   GPx↓, 2,   GSH↓, 9,   GSR↓, 1,   GSTs↓, 1,   HO-1↓, 2,   HO-1↑, 1,   MDA↑, 1,   NQO1↓, 1,   NQO1↑, 1,   NRF2↓, 3,   NRF2↑, 3,   NRF2↝, 1,   OXPHOS↑, 1,   ROS↓, 2,   ROS↑, 20,   mt-ROS↑, 1,   SIRT3↑, 3,   SOD↓, 4,   SOD↑, 1,   SOD1↑, 1,   SOD2↓, 1,   SOD2↑, 2,   Trx1↑, 1,   TrxR↓, 1,   VitC↓, 1,   VitE↓, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   ATP↓, 1,   BOK↑, 1,   CDC2↓, 2,   EGF↓, 1,   MEK↓, 1,   mitResp↓, 1,   MKK4↓, 1,   MMP↓, 7,   MPT↑, 1,   mtDam↑, 2,   OCR↓, 2,   Raf↓, 1,   c-Raf↓, 1,   XIAP↓, 3,  

Core Metabolism/Glycolysis ⓘ

AKT1↓, 1,   AMPK↑, 3,   ATG7↑, 1,   cMyc↓, 4,   p‑cMyc↑, 1,   CYP3A4↓, 1,   Glycolysis↓, 3,   HK2↓, 1,   IDH1↑, 1,   LDHA↓, 1,   NADPH↓, 1,   PKM2↓, 5,   SIRT1↓, 1,   SIRT1↑, 1,   Warburg↓, 1,  

Cell Death ⓘ

Akt↓, 13,   Akt↑, 1,   p‑Akt↓, 4,   APAF1↑, 1,   Apoptosis↑, 14,   BAD↑, 1,   Bak↑, 1,   BAX↑, 10,   BAX↝, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 8,   BID↑, 1,   BIM↑, 1,   BMP2↓, 1,   Casp1↓, 1,   cl‑Casp12↑, 1,   cl‑Casp12↝, 1,   Casp3↑, 10,   cl‑Casp3↑, 3,   Casp7↑, 1,   Casp8↑, 3,   cl‑Casp8↑, 2,   Casp9↑, 5,   cl‑Casp9↑, 1,   proCasp9↓, 1,   cFLIP↓, 1,   Cyt‑c↑, 6,   DR4↑, 1,   DR5↑, 6,   FADD↑, 1,   Fas↑, 5,   FasL↑, 1,   HGF/c-Met↓, 1,   hTERT/TERT↓, 3,   iNOS↓, 1,   JNK↑, 2,   p‑JNK↑, 1,   MAPK↓, 6,   MAPK↑, 2,   Mcl-1↓, 3,   Mcl-1↑, 1,   MDM2↓, 3,   p‑MDM2↓, 1,   NAIP↓, 1,   Necroptosis↑, 1,   NICD↓, 1,   p38↓, 1,   p‑p38↑, 1,   survivin↓, 5,   Telomerase↓, 3,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

EF-1α↓, 1,   HER2/EBBR2↓, 1,   p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 2,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   cJun↑, 1,   EZH2↓, 1,   H3↓, 1,   H3↑, 1,   H4↓, 1,   H4↑, 1,   HATs↑, 1,   other↝, 1,   pRB↓, 1,   tumCV↓, 5,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   p‑CHOP↝, 1,   cl‑CHOP↑, 1,   eIF2α↑, 1,   p‑eIF2α↑, 2,   p‑eIF2α↝, 1,   ER Stress↑, 5,   GRP78/BiP↑, 1,   PERK↑, 1,   p‑PERK↝, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 2,   BNIP3↑, 1,   LC3B-II↑, 1,   LC3II↑, 3,   TumAuto↑, 4,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,   P53↑, 6,   P53↝, 1,   PARP↑, 1,   cl‑PARP↑, 4,   PCNA↓, 3,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 7,   CDK4↓, 5,   cycA1/CCNA1↑, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 8,   cycE/CCNE↓, 1,   E2Fs↓, 1,   P21?, 1,   P21↑, 3,   RB1↓, 1,   p‑RB1↓, 1,   TumCCA↑, 12,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD34↓, 1,   CD44↓, 1,   cFos↓, 2,   cFos↑, 1,   cMET↓, 2,   CSCs↓, 6,   CSCsMark↓, 1,   EMT↓, 47,   EMT↑, 1,   ERK↓, 5,   ERK↑, 1,   p‑ERK↓, 3,   p‑FOXO3↓, 1,   GSK‐3β↓, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 2,   LRP6↓, 3,   p‑LRP6↓, 1,   mTOR↓, 10,   p‑mTOR↓, 2,   mTORC1↓, 2,   Nanog↓, 2,   Nestin↓, 1,   NOTCH↓, 2,   NOTCH1↓, 3,   NOTCH3↓, 1,   OCT4↓, 2,   P70S6K↓, 2,   PI3K↓, 10,   p‑PI3K↓, 2,   PTEN↓, 1,   RAS↓, 2,   SOX2↓, 2,   p‑Src↓, 1,   STAT3↓, 11,   p‑STAT3↓, 2,   p‑STAT6↓, 1,   TAZ↓, 1,   TOP2↓, 1,   TumCG↓, 7,   Wnt↓, 6,  

Migration ⓘ

AEG1↓, 1,   Akt2↓, 1,   AXL↓, 1,   Ca+2↑, 4,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 2,   E-cadherin↓, 4,   E-cadherin↑, 16,   F-actin↓, 2,   FAK↓, 4,   ITGA5↓, 2,   ITGB1↓, 4,   ITGB6↓, 1,   Ki-67↓, 2,   MALAT1↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP2↓, 11,   MMP9↓, 13,   MMPs↓, 4,   N-cadherin↓, 17,   Rac1↓, 1,   Rho↓, 2,   ROCK1↓, 1,   Slug↓, 8,   Smad1↓, 1,   SMAD2↓, 1,   p‑SMAD2↓, 5,   SMAD3↓, 2,   p‑SMAD3↓, 4,   Snail↓, 16,   SOX4↓, 1,   TGF-β↓, 5,   TGF-β1↓, 1,   TIMP1↑, 1,   TIMP2↑, 1,   TumCI↓, 19,   TumCMig↓, 18,   TumCP↓, 12,   TumMeta↓, 8,   Twist↓, 4,   Tyro3↓, 1,   uPA↓, 1,   Vim↓, 15,   Vim↑, 1,   Zeb1↓, 6,   ZEB2↓, 1,   ZO-1↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 10,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 8,   ATF4↑, 2,   p‑ATF4↝, 1,   EGFR↓, 6,   EGFR↑, 1,   p‑EGFR↓, 1,   Hif1a↓, 7,   NO↝, 1,   VEGF↓, 9,   VEGFR2↓, 3,  

Barriers & Transport ⓘ

BBB↓, 1,   BBB↑, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   COX2↓, 7,   CXCR4↓, 1,   HMGB1↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   IKKα↓, 3,   IKKα↑, 1,   IL1↓, 1,   IL2↑, 1,   IL6↓, 6,   IL8↓, 1,   Inflam↓, 1,   JAK1↓, 2,   JAK2↓, 1,   NF-kB↓, 13,   p‑NF-kB↑, 1,   p65↓, 1,   p65↑, 1,   p‑p65↓, 1,   PD-1↓, 1,   PGE2↓, 2,   PSA↓, 1,   TNF-α↓, 4,  

Cellular Microenvironment ⓘ

pH↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 3,   CDK6↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 3,   BioAv↝, 1,   ChemoSen↓, 1,   ChemoSen↑, 13,   CYP1A2↑, 1,   CYP2A3/CYP2A6↓, 1,   Dose↓, 2,   Dose↝, 2,   eff↓, 1,   eff↑, 5,   Half-Life↓, 2,   Half-Life↝, 1,   Half-Life∅, 1,   MDR1↓, 1,   P450↓, 1,   RadioS↑, 6,   selectivity↑, 7,  

Clinical Biomarkers ⓘ

AR↓, 3,   CA125↓, 1,   CEA↓, 1,   EGFR↓, 6,   EGFR↑, 1,   p‑EGFR↓, 1,   EZH2↓, 1,   GutMicro↑, 1,   HER2/EBBR2↓, 1,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 3,   IL6↓, 6,   Ki-67↓, 2,   NSE↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 3,   cachexia↓, 1,   cardioP↑, 2,   chemoP↑, 2,   chemoPv↑, 1,   OS↑, 4,   Pin1↓, 1,   Risk↓, 1,   Symptoms∅, 1,   toxicity↓, 2,   TumW↓, 1,  
Total Targets: 343

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 5,   Catalase↑, 3,   GPx↓, 1,   GPx↑, 1,   GPx1↑, 1,   GSH↑, 5,   GSR↑, 1,   GSTs↑, 2,   lipid-P↓, 3,   MDA↓, 1,   MPO↓, 1,   NRF2↑, 2,   ROS↓, 6,   SOD↑, 4,   SOD1↑, 1,   SOD2↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   LDHA↑, 1,   PKM2↓, 1,  

Cell Death ⓘ

Akt↑, 1,   Casp3↓, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 2,   p‑P70S6K↓, 1,   PI3K↑, 1,  

Migration ⓘ

COL1↓, 1,   COL3A1↓, 1,   E-cadherin↑, 1,   Fibronectin↓, 1,   MMP2↓, 1,   MMP9↓, 1,   Smad7↑, 1,   TGF-β↓, 2,   Vim↓, 1,   α-SMA↓, 3,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,   NO↓, 1,  

Barriers & Transport ⓘ

BBB↑, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IFN-γ↑, 1,   IL10↓, 1,   IL10↑, 1,   IL1β↓, 2,   IL5↓, 1,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 3,   Dose↝, 2,   eff↑, 1,   Half-Life↝, 2,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   GutMicro↝, 1,   IL6↓, 2,  

Functional Outcomes ⓘ

hepatoP↑, 2,   neuroP↑, 3,   toxicity↓, 2,   toxicity↝, 1,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 71

Scientific Paper Hit Count for: EMT, Epithelial-Mesenchymal Transition
19 Curcumin
16 Resveratrol
15 Quercetin
12 Honokiol
10 Sulforaphane (mainly Broccoli)
9 Ashwagandha(Withaferin A)
9 Thymoquinone
8 EGCG (Epigallocatechin Gallate)
8 Fisetin
6 Astragalus
6 Berberine
6 Luteolin
6 Metformin
6 Piperine
6 Rosmarinic acid
5 Apigenin (mainly Parsley)
5 Betulinic acid
5 Chrysin
5 Eugenol
5 Silymarin (Milk Thistle) silibinin
4 Alpha-Lipoic-Acid
4 Baicalein
4 Propolis -bee glue
4 Chlorogenic acid
4 Pterostilbene
4 Shikonin
3 Artemisinin
3 Atorvastatin
3 Cyclopamine
3 salinomycin
3 Genistein (soy isoflavone)
3 Emodin
3 Ferulic acid
3 HydroxyTyrosol
3 Lycopene
3 Piperlongumine
3 Urolithin
2 Anethole/trans-Anethole
2 Astaxanthin
2 brusatol
2 Capsaicin
2 Cannabidiol
2 Celecoxib
2 Crocetin
2 5-fluorouracil
2 Dandelion Root
2 Disulfiram
2 Ellagic acid
2 Fucoidan
2 Garcinol
2 Grapeseed extract
2 Naringin
2 Nimbolide
2 Phenethyl isothiocyanate
2 Vitamin C (Ascorbic Acid)
2 Vitamin D3
2 VitK3,menadione
1 Anthocyanins
1 Allicin (mainly Garlic)
1 alpha Linolenic acid
1 Cisplatin
1 Aspirin
1 Baicalin
1 Berbamine
1 Biochanin A
1 Brucea javanica
1 Boron
1 Caffeic acid
1 Carnosic acid
1 Cucurbitacin
1 Radiotherapy/Radiation
1 Oxaliplatin
1 Dichloroacetate
1 Deguelin
1 Docosahexaenoic Acid
1 immunotherapy
1 Copper and Cu NanoParticles
1 Evodiamine
1 Beta-Caryophyllene
1 Cinnamon
1 Shilajit/Fulvic Acid
1 Gallic acid
1 Paclitaxel
1 Proanthocyanidins
1 Hydroxycinnamic-acid
1 Ivermectin
1 Sorafenib (brand name Nexavar)
1 Juglone
1 Licorice
1 Lactoferrin
1 methotrexate
1 Magnolol
1 Myricetin
1 Niclosamide (Niclocide)
1 Oleocanthal
1 Plumbagin
1 Psoralidin
1 isoflavones
1 Sanguinarine
1 Selenium
1 Selenate
1 Gemcitabine (Gemzar)
1 Selenite (Sodium)
1 statins
1 Citric Acid
1 Thymol-Thymus vulgaris
1 Ursolic acid
1 Vitamin K2
1 Zinc
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:96  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page